- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11.25 | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Teknova reiterates $39M-$42M 2025 revenue target while eyeing 20%-25% long-term growth amid operational advances | 2 | Seeking Alpha | ||
| 06.11.25 | Alpha Teknova GAAP EPS of -$0.08 beats by $0.01, revenue of $10.5M beats by $0.27M | 1 | Seeking Alpha | ||
| 06.11.25 | Alpha Teknova, Inc.: Teknova Reports Third Quarter 2025 Financial Results | 86 | GlobeNewswire (Europe) | Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million... ► Artikel lesen | |
| 28.10.25 | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 | 4 | GlobeNewswire (USA) | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 20.10.25 | Alpha Teknova (TKNO) Surged Following Accelerated Demand | 2 | Insider Monkey | ||
| 01.09.25 | Does Alpha Teknova (TKNO) Have Meaningful Growth Opportunities? | 2 | Insider Monkey | ||
| 08.08.25 | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.03.25 | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 549 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 77,70 | +0,69 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,900 | -4,99 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 81,26 | -3,09 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,72 | -0,29 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 36,850 | -1,21 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,440 | +33,33 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| OLEMA PHARMACEUTICALS | 26,340 | +0,77 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| QIAGEN | 43,845 | -0,43 % | QIAGEN N.V.: QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 | QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible protocols, compact design and sustainability-focused features QIAGEN... ► Artikel lesen | |
| ALUMIS | 26,350 | -2,62 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TARSUS PHARMACEUTICALS | 63,51 | -4,93 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| BIONTECH | 92,50 | +1,09 % | BioNTech ernennt Kylie Jimenez zur Chief People Officer | Der Aufsichtsrat der BioNTech SE hat Kylie Jimenez mit Wirkung zum 1. März 2026 zur neuen Chief People Officer (Chief People Officer) ernannt. Die neu geschaffene Vorstandsposition umfasst die Verantwortung... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,910 | -0,29 % | MEDICAL BioHealth Fonds: Eli Lilly kauft Ventyx Biosciences | Gräfelfing (www.fondscheck.de) - Anbei eine aktuelle Pressemitteilung der Medical Strategy GmbH:Zum Kauf von Ventyx Biosciences durch Eli Lilly ein Statement von Mario Linimeier, Geschäftsführer der... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 303,34 | -2,15 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| SUMMIT THERAPEUTICS | 14,430 | -1,10 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock |
ALPHA TEKNOVA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,120 (-4,92 %) liegt der Kurs bei 2,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.